Rv1379 Uracil phosphoribosyltransferase (EC / Pyrimidine operon regulatory protein PyrR

Symbol Product Feature Type Start End Strand Length AA Length is TF
Rv1379 pyrR Uracil phosphoribosyltransferase (EC / Pyrimidine operon regulatory protein PyrR CDS 1552654 1553235 + 582 193 TRUE

Rv1379 (Uracil phosphoribosyltransferase (EC / Pyrimidine operon regulatory protein PyrR) is predicted to be co-regulated in modules bicluster_0137 with residual 0.49 and bicluster_0484 with residual 0.42.

This regulation is possibly mediated by two de-novo identified cis-regulatory motifs in each module with e-values , 850.00 and 1,200.00 for bicluster_0137 and 270.00 and 200.00 for bicluster_0484 respectively.

These modules are enriched for following go terms: 'de novo' pyrimidine nucleobase biosynth..., pyrimidine-containing compound biosynthe..., pyrimidine-containing compound metabolic..., organonitrogen compound metabolic proces..., nucleobase-containing small molecule met..., carbon-nitrogen ligase activity, with gl... .

This gene is found to be for growth on cholesterol.

Mutant available?:

Displaying 1 - 3 of 3
Gene Target Differential Expression Distance Expression pvalue Type
No -31 0.07 0.994124 CDS
Probable phiRV1 phage protein
No -47 0.34 0.979055 CDS
FIG055075: Possibly a cell division protein, antigen 84 in Mycobacteria
No 63 0.05 0.98079 Primary.TSS
Product (LegacyBRC) Product (RefSeq)
Bifunctional protein pyrR bifunctional pyrimidine regulatory protein PyrR uracil phosphoribosyltransferase
Operon # Operon
928 - - - - - -
PATRIC Locus Tag Enzyme Name PATRIC Pathways Transcriptomics


Uracil phosphoribosyltransferase Pyrimidine metabolism
Locus Tuberculist Genome View


Locus Tag KEGG Pathways


Pyrimidine metabolism

Total items in this category:  


Metabolic pathways

Total items in this category:  
BioCyc Gene Page Cellular Overview Map
Link to STRING STRING Network


GI Number Protein ID Blast Conserved Domains
15608519 NP_215895.1 Run
Description:Expression data from transcription factor over expression experiments. TFOE are matched to the ChIP-seq experiment done simultaneously. This dataset is described in Rustad et al. 2014, Genome Biology.
BioProject Accession GEO Series References Repository Sample Method Sample Type
PRJNA254351 GSM1426667 GSE59086 25232098 GEO Tiling Array RNA
PRJNA254351 GSM1426668 GSE59086 25232098 GEO Tiling Array RNA
PRJNA254351 GSM1426669 GSE59086 25232098 GEO Tiling Array RNA
Experiment UCSC Genome Browser
Rv1379_B439 UCSC Browser Tracks
Quantitative Proteomics Data
t-test p-value Cholesterol/Glycerol Ratio

How essentiality calculations were done?

The relative representation of each mutant was determined by calculating the fold change (sequence reads/insertion in cholesterol divided by sequence reads/insertion in glycerol) for each gene. Statistical significance was determined by t-test. Each insertion site in each replicate sample was treated as a separate data point. The hyperbola used for defining genes specifically required for growth in cholesterol was defined by the formula, y = 3.8/x+0.7. Genes above this line are annotated as required for growth on cholesterol.

TRIP log2 fold abundance change

reports the log2 abundance fold change of each TFI strain, relative to no induction, in absence or presence of drug, averaged across experimental replicates. Also reported are the accompanying z-scores and two-sided t-test p-values for each TFI strain under each condition. Please refer to Ma et al., 2020, Nature Microbiology for more information.

p-value Untreated: 0.804636
p-value INH: 0.863689
Displaying 1 - 17 of 17
Condition Count Day Doublings Fitness U.I Plots
D0U 27 0 0.00 8.41 U
D3I 3 3 3.83 13.19 I
D3U 3 3 3.83 13.56 U
D5I 9 5 6.00 I
D5U 17 5 6.00 U
D7I 18 7 8.14 6.90 I
D7U 19 7 8.14 6.28 U
D14I 4 14 15.63 8.71 I
D14U 4 14 15.63 7.15 U
D17I 3 17 19.15 6.20 I
D17U 3 17 19.15 3.99 U
D21I 4 21 23.23 5.58 I
D21U 4 21 23.23 7.09 U
D24I 3 24 26.60 3.35 I
D24U 3 24 26.60 U
D28I 4 28 30.61 4.60 I
D28U 4 28 30.61 5.18 U